

Erratum to: Linagliptin: a review of its use in the management of type 2 diabetes mellitus

Emma D. Deeks

Published online: 22 January 2013
© Springer International Publishing Switzerland 2013

Erratum to: Drugs (2012) 72:1793–1824
DOI 10.2165/11209570-000000000-00000

Page 1804, column 1, section 5.3.1, paragraph 2, which previously read:

“Significantly^[12] or numerically^[11,54] more patients in the linagliptin than in the placebo groups achieved an HbA_{1c} level of $\leq 7.0\%$ (table IV)^[11,12] or $< 6.5\%$ (10% vs 2%; OR 5.5; $p < 0.0016$),^[12] a reduction in HbA_{1c} of $\geq 0.5\%$ (table IV)^[12,54] or required rescue therapy (8% vs 19%; OR 0.28; $p = 0.0001$).^[12]”

Should read:

“Significantly^[12] or numerically^[11,54] more patients in the linagliptin than in the placebo groups achieved an HbA_{1c} level of $\leq 7.0\%$ (table IV)^[11,12] or $< 6.5\%$ (10% vs 2%; OR 5.5; $p < 0.0016$)^[12] or a reduction in HbA_{1c} of $\geq 0.5\%$ (table IV),^[12,54] and significantly fewer linagliptin than placebo recipients required rescue therapy (8% vs 19%; OR 0.28; $p = 0.0001$).^[12]”

The online version of the original article can be found under doi:[10.2165/11209570-000000000-00000](https://doi.org/10.2165/11209570-000000000-00000).

E. D. Deeks (✉)
Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay,
North Shore 0754, Auckland, New Zealand
e-mail: demail@springer.com